BGB-16673, a first-in-class BTK degrader, is being studied for relapsed or refractory persistent lymphocytic leukemia (CLL) in a part 1 trial, in keeping with Dr. Lydia Scarfò. Not like BTK inhibitors that block enzyme exercise, this agent results in the degradation of the BTK protein, which performs a key position in CLL cell progress.
Up to date trial findings, which had been introduced on the 2025 European Hematology Affiliation (EHA) Congress, included extra sufferers and longer follow-up than beforehand reported. Whereas the research continues to discover the drug’s potential throughout B-cell malignancies, the protection profile stays a key focus.
To this point, uncomfortable side effects have been in line with expectations for BTK-targeted therapies. The most typical problem has been neutropenia, which has usually been manageable with G-CSF help. Atrial fibrillation was reported in two sufferers — one with a previous historical past and one throughout a interval of illness development and an infection. There have been additionally two instances of main bleeding as mentioned by Scarfò. No new or sudden security issues have been recognized to this point, and the early knowledge counsel that BGB-16673 is tolerable for many sufferers.
Scarfò is a doctor scientist on the B-cell neoplasia Unit and an assistant professor at Università Vita-Salute San Raffaele, Milano, Italy.
Transcript
Are you able to clarify to sufferers whether or not there are any notable security issues or uncomfortable side effects reported with this agent, and the way they’re being managed?
Within the part 1/2 trial, an important focus is on security. Primarily based on the observations up to now, there have been no sudden scientific signs. The most typical or frequent aspect impact has been neutropenia, which is mostly manageable with G-CSF help.
We additionally noticed two instances of atrial fibrillation — one in a affected person with a historical past of atrial fibrillation, and one other throughout a interval of illness development and an infection. There have been additionally two main bleeding occasions, thought-about related as a consequence of their severity.
General, the protection profile of BGB-16673 seems to be tolerable and manageable, in line with what we’ve seen from earlier brokers like covalent BTK inhibitors.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
